Eligibility and utilization of implantable cardioverter-defibrillators in a regional STEMI system

Benjamin K. Johnson, Ross F. Garberich, Timothy D. Henry, William T. Katsiyiannis, Jay Sengupta, Ankur Kalra, Robert G. Hauser, Meghan E. Lardy, Marc C. Newell

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background Studies have shown mortality benefit for implantable cardioverter-defibrillators (ICDs) in ST-elevation myocardial infarction (STEMI) patients with reduced left ventricular ejection fraction (LVEF), but contemporary eligibility and appropriate utilization of ICDs is unknown. Objective The purpose of this study was to determine the contemporary eligibility and appropriate utilization of ICDs post-STEMI. Methods Using the prospective Minneapolis Heart Institute regional STEMI registry, LVEF before discharge and at follow-up were stratified into 3 groups: normal (LVEF ≥50%), mildly reduced (LVEF 35%-49%), and severely reduced (LVEF <35%). Results From March 2003 to June 2012, 3626 patients were treated. Patients with in-hospital death (n = 187), ICD in place (n = 21), negative cardiac biomarkers (n = 337), and undocumented in-hospital LVEF (n = 9) were excluded, leaving 3072 patients in the final analysis, including 1833 (59.7%) with LVEF ≥50%, 875 (28.5%) with LVEF between 35% and 49%, and 364 (11.8%) with LVEF <35% before hospital discharge. Overall, 1029 patients (33.5%) underwent follow-up echocardiography ≥40 days post-STEMI, including 140 of the 364 patients (38.5%) discharged with LVEF <35%. In total, 73 patients (7.1%) with follow-up echocardiography ≥40 days post-STEMI met criteria for an ICD (68 LVEF ≤30%, 5 LVEF 30%-35%, and New York Heart Association class II or greater). Only 26 of these patients (35.6%) underwent ICD placement within 1 year post-STEMI. Overall, only 10% to 15% of potentially eligible patients had an ICD implemented. Conclusion Rates of ICD implantation in appropriate STEMI patients after 40 days are low. Strategies are needed to identify and expand access to these high-risk patients.

Original languageEnglish (US)
Pages (from-to)538-546
Number of pages9
JournalHeart Rhythm
Issue number2
StatePublished - Feb 1 2016

Bibliographical note

Funding Information:
This research was supported by the Minneapolis Heart Institute Foundation.

Publisher Copyright:
© 2016 Heart Rhythm Society.


  • Implantable cardioverter-defibrillator
  • Ischemic cardiomyopathy
  • Left ventricular ejection fraction
  • ST-elevation myocardial infarction


Dive into the research topics of 'Eligibility and utilization of implantable cardioverter-defibrillators in a regional STEMI system'. Together they form a unique fingerprint.

Cite this